Total Payments
$435,661
2024 Payments
$3,848
Companies
11
Transactions
61
Medicare Patients
3,765
Medicare Billing
$298,952
Payment Breakdown by Category
Research$431,437 (99.0%)
Travel$2,626 (0.6%)
Food & Beverage$1,248 (0.3%)
Other$330.00 (0.1%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $431,437 | 41 | 99.0% |
| Travel and Lodging | $2,626 | 7 | 0.6% |
| Food and Beverage | $1,248 | 11 | 0.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $330.00 | 1 | 0.1% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$431,437
41 transactions
General
$4,224
20 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Becton, Dickinson and Company | $311,750 | 7 | $0 (2021) |
| Eli Lilly and Company | $90,685 | 22 | $0 (2023) |
| PFIZER INC. | $24,010 | 16 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $6,175 | 5 | $0 (2023) |
| Amryt Pharma Holdings Ltd | $2,715 | 3 | $0 (2022) |
| Smith & Nephew, Inc. | $152.50 | 2 | $0 (2018) |
| Allergan Inc. | $78.86 | 1 | $0 (2019) |
| Dexcom, Inc. | $29.70 | 2 | $0 (2023) |
| Medline Industries LP | $27.94 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $22.06 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,848 | 3 | PFIZER INC. ($3,820) |
| 2023 | $3,930 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($2,850) |
| 2022 | $13,555 | 9 | PFIZER INC. ($10,540) |
| 2021 | $9,391 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($3,325) |
| 2020 | $85,136 | 5 | Becton, Dickinson and Company ($51,604) |
| 2019 | $141,001 | 7 | BECTON, DICKINSON AND COMPANY ($139,850) |
| 2018 | $154,134 | 14 | Becton, Dickinson and Company ($113,965) |
| 2017 | $24,667 | 11 | Eli Lilly and Company ($21,145) |
All Payment Transactions
61 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 09/29/2024 | PFIZER INC. | — | — | In-kind items and services | $620.00 | Research |
| Study: NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 01/26/2024 | Medline Industries LP | Medline Industries, Inc. (Device) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: Medical Supplies | ||||||
| 06/08/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | — | Cash or cash equivalent | $950.00 | Research |
| Study: PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM • Category: INTERNAL MEDICINE | ||||||
| 04/26/2023 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | — | Cash or cash equivalent | $1,900.00 | Research |
| Study: PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM • Category: INTERNAL MEDICINE | ||||||
| 02/01/2023 | PFIZER INC. | — | — | In-kind items and services | $780.00 | Research |
| Study: PREVNAR 7 CLINICAL PUBLICATION PROGRAM | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $285.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 01/04/2023 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Endocrinology | ||||||
| 11/28/2022 | PFIZER INC. | PREVNAR 13 (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 11/02/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Endocrinology | ||||||
| 10/02/2022 | PFIZER INC. | COMIRNATY (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: COVID19 VACC CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 09/29/2022 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | — | Cash or cash equivalent | $1,084.52 | Research |
| Study: MACRO Registry • Category: Endocrinology | ||||||
| 07/21/2022 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | — | Cash or cash equivalent | $1,018.95 | Research |
| Study: MACRO Registry • Category: Endocrinology | ||||||
| 07/21/2022 | Amryt Pharma Holdings Ltd | MYCAPSSA (Drug) | — | Cash or cash equivalent | $611.37 | Research |
| Study: MACRO Registry • Category: Endocrinology | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $285.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | ||||||
| 04/19/2022 | PFIZER INC. | PREVNAR 13 (Biological) | — | In-kind items and services | $940.00 | Research |
| Study: PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 02/28/2022 | PFIZER INC. | COMIRNATY (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: COVID19 VACC CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 11/19/2021 | Abbott Laboratories | FreeStyle Libre 2 (Device) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes Care | ||||||
| 08/19/2021 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | — | Cash or cash equivalent | $2,375.00 | Research |
| Study: PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM • Category: INTERNAL MEDICINE | ||||||
| 07/29/2021 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | — | Cash or cash equivalent | $475.00 | Research |
| Study: PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM • Category: INTERNAL MEDICINE | ||||||
| 06/18/2021 | PFIZER INC. | — | — | In-kind items and services | $3,200.00 | Research |
| Study: RESPIRATORY SYNCYTIAL VIRUS CLINICAL PUBLICATION PROGRAM | ||||||
| 06/17/2021 | Takeda Pharmaceuticals U.S.A., Inc. | NATPARA (PARATHYROID HORMONE) (Drug) | — | Cash or cash equivalent | $475.00 | Research |
| Study: PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM • Category: INTERNAL MEDICINE | ||||||
| 06/04/2021 | PFIZER INC. | — | Gift | In-kind items and services | $20.00 | General |
| 02/02/2021 | Becton, Dickinson and Company | — | — | Cash or cash equivalent | $2,831.25 | Research |
| Study: BRIGHT • Category: Diabetes Care | ||||||
| 10/25/2020 | PFIZER INC. | — | — | In-kind items and services | $940.00 | Research |
| Study: PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| NUCLS07 | Becton, Dickinson and Company | $117,465 | 2 |
| PENDL02 | BECTON, DICKINSON AND COMPANY | $77,120 | 1 |
| PENDL01 | BECTON, DICKINSON AND COMPANY | $56,730 | 1 |
| BRIGHT | Becton, Dickinson and Company | $54,435 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $29,677 | 3 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | Eli Lilly and Company | $27,227 | 4 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $21,806 | 3 |
| PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,280 | 4 |
| COVID19 VACC CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,400 | 2 |
| PARADIGHM A NATURAL HISTORY REGISTRY FOR PATIENTS WITH CHRONIC HYPOPARATHYROIDISM | Takeda Pharmaceuticals U.S.A., Inc. | $6,175 | 5 |
| BRIGHT | BECTON, DICKINSON AND COMPANY | $6,000 | 1 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $5,480 | 2 |
| NONCOVERED PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,820 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM STUDY OF THE EFFICACY AND SAFETY OF INVESTIGATIONAL DULAGLUTIDE DOSES WHEN ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $3,741 | 2 |
| RESPIRATORY SYNCYTIAL VIRUS CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| MACRO Registry | Amryt Pharma Holdings Ltd | $2,715 | 3 |
| PREVNAR 7 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $780.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $285.00 | 1 |
| A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, 18-WEEK TRIAL OF INVESTIGATIONAL DULAGLUTIDE DOSES VERSUS PLACEBO IN PATIENTS WITH TYPE 2 DIABETES ON METFORMIN MONOTHERAPY | Eli Lilly and Company | $101.44 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 811 | 1,505 | $161,635 | $76,366 |
| 2022 | 13 | 862 | 1,428 | $155,744 | $73,366 |
| 2021 | 11 | 823 | 1,441 | $159,511 | $81,387 |
| 2020 | 15 | 1,269 | 2,034 | $175,689 | $67,834 |
Total Patients
3,765
Total Services
6,408
Medicare Billing
$298,952
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 283 | 664 | $118,160 | $60,441 | 51.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 66 | 85 | $9,792 | $4,670 | 47.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 19 | 19 | $6,496 | $3,188 | 49.1% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 98 | 183 | $8,537 | $1,695 | 19.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 166 | 239 | $1,752 | $1,692 | 96.6% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 79 | 108 | $7,690 | $1,370 | 17.8% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 23 | 50 | $3,225 | $1,263 | 39.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 27 | 101 | $3,172 | $1,128 | 35.6% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2023 | 15 | 15 | $2,168 | $786.93 | 36.3% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 35 | 41 | $643.00 | $131.61 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 236 | 510 | $90,772 | $46,550 | 51.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 125 | 187 | $21,537 | $12,344 | 57.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $6,806 | $3,562 | 52.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 20 | 26 | $5,850 | $2,287 | 39.1% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 35 | 75 | $5,033 | $2,105 | 41.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 22 | 23 | $4,894 | $1,465 | 29.9% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 103 | 150 | $6,993 | $1,391 | 19.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 24 | 104 | $3,267 | $1,079 | 33.0% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 66 | 84 | $5,978 | $1,062 | 17.8% |
| 95249 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin | Office | 2022 | 15 | 16 | $2,312 | $803.04 | 34.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 133 | 162 | $1,187 | $473.07 | 39.8% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 49 | 57 | $894.93 | $175.08 | 19.6% |
| 82948 | Blood glucose (sugar) measurement using reagent strip | Office | 2022 | 14 | 14 | $219.80 | $70.36 | 32.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 245 | 624 | $111,072 | $60,203 | 54.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 161 | 223 | $25,689 | $15,170 | 59.1% |
About Dr. David Fitz-Patrick, M.D
Dr. David Fitz-Patrick, M.D is a Specialist healthcare provider based in Honolulu, Hawaii. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/13/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275531154.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Fitz-Patrick, M.D has received a total of $435,661 in payments from pharmaceutical and medical device companies, with $3,848 received in 2024. These payments were reported across 61 transactions from 11 companies. The most common payment nature is "" ($431,437).
As a Medicare-enrolled provider, Fitz-Patrick has provided services to 3,765 Medicare beneficiaries, totaling 6,408 services with total Medicare billing of $298,952. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Honolulu, HI
- Active Since 07/13/2005
- Last Updated 09/23/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1275531154
Products in Payments
- BD Nano (Device) $113,965
- COMIRNATY (Biological) $6,400
- NATPARA (PARATHYROID HORMONE) (Drug) $6,175
- PREVNAR 13 (Biological) $4,140
- TRULICITY (Drug) $3,842
- MYCAPSSA (Drug) $2,715
- PREVNAR - 13 (Biological) $330.00
- Navio Surgical System (Device) $152.50
- Dexcom G6 Transmitter (Medical Supply) $29.70
- Medline Industries, Inc. (Device) $27.94
- ADVAIR (Drug) $22.06
- FreeStyle Libre 2 (Device) $15.00
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Honolulu
Dr. Douglas Johnson, M.d, M.D
Specialist — Payments: $740,679
Specialist $740,679
Laurie Tom, M.d, M.D
Specialist — Payments: $152,468
Specialist $152,468
Dr. Cecilia Shikuma, M.d, M.D
Specialist — Payments: $65,372
Specialist $65,372
Dr. Anthony Hernandez, M.d, M.D
Specialist — Payments: $48,896
Specialist $48,896
Dr. Kenneth Kaan, Md, MD
Specialist — Payments: $40,989
Specialist $40,989
Dr. Mihae Yu
Specialist — Payments: $36,863
Specialist $36,863